Related Experiment Videos
Pharmacogenomics in Asia
Mieko Tamaoki1, Hiroshi Gushima, Kiichiro Tsutani
1Product Evaluation Department, Yamanouchi Pharmaceutical Co. Ltd., Tokyo, Japan. tamaoki@yamanouchi.co.jp
Pharmacogenomics
|December 9, 2004
Summary
Pharmacogenetic and pharmacogenomic research in Asian populations is crucial for drug development. This study highlights significant, yet underrecognized, activities in China, Japan, South Korea, Singapore, and Taiwan.
Area of Science:
- Pharmacogenomics
- Genetics
- Drug Development
Background:
- Genetic polymorphisms, like single nucleotide polymorphisms (SNPs), exhibit racial variations.
- Pharmacogenetic/pharmacogenomic data from Asian populations are essential for global drug development and clinical practice.
- Understanding these variations is key to personalized medicine.
Purpose of the Study:
- To investigate the current status of pharmacogenetic/pharmacogenomic activities in five Asian countries.
- To analyze ongoing research, guideline development, and clinical trial implementation in the region.
Main Methods:
- Research and analysis of pharmacogenetic/pharmacogenomic activities.
- Review of national guidelines and initiatives.
- Identification of clinical trials related to pharmacogenetics/pharmacogenomics in the selected countries.
Main Results:
- Multiple pharmacogenetic/pharmacogenomic initiatives are active across China, Japan, South Korea, Singapore, and Taiwan.
- These activities include guideline development and foundational projects.
- Several relevant clinical trials are underway but have received limited recognition.
Conclusions:
- Significant progress in pharmacogenetics/pharmacogenomics is being made in key Asian countries.
- These efforts, including clinical trials, warrant greater recognition within the global scientific community.
- Increased awareness can foster collaboration and advance personalized medicine in Asia.